Evaluation of glutaminase expression in prostate adenocarcinoma and correlation with clinicopathologic parameters

Zin W. Myint; Ramon C. Sun; Patrick J. Hensley; Andrew C. James; Peng Wang; Stephen E. Strup; Robert J. McDonald; Donglin Yan; William H. St. Clair; Derek B. Allison

doi:10.3390/cancers13092157

Evaluation of glutaminase expression in prostate adenocarcinoma and correlation with clinicopathologic parameters

Zin W. Myint, Ramon C. Sun, Patrick J. Hensley, Andrew C. James, Peng Wang, Stephen E. Strup, Robert J. McDonald, Donglin Yan, William H. St. Clair, Derek B. Allison

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

High Glutaminase (GLS1) expression may have prognostic implications in colorectal and breast cancers; however, high quality data for expression in prostate cancer (PCa) are lacking. The purpose of this study is to investigate the status of GLS1 expression in PCa and correlated expression levels with clinicopathologic parameters. This study was conducted in two phases: an exploratory cohort analyzing RNA-Seq data for GLS1 from The Cancer Genome Atlas (TCGA) data portal (246 PCa samples) and a GLS1 immunohistochemical protein expression cohort utilizing a tissue microarray (TMA) (154 PCa samples; 41 benign samples) for correlation with clinicopathologic parameters. In the TCGA cohort, GLS1 mRNA expression did not show a statistically significant difference in disease-free survival (DFS) but did show a small significant difference in overall survival (OS). In the TMA cohort, there was no correlation between GLS1 expression and stage, Gleason score, DFS and OS. GLS1 expression did not significantly correlate with the clinical outcomes measured; however, GLS1 expression was higher in PCa cells compared to benign epithelium. Future studies are warranted to evaluate expression levels in greater numbers of high-grade and advanced PCa samples to investigate whether there is a rational basis for GLS1 targeted therapy in a subset of patients with prostate cancer.

Original language	English
Article number	2157
Journal	Cancers
Volume	13
Issue number	9
DOIs	https://doi.org/10.3390/cancers13092157
State	Published - May 1 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Funding

The University of Kentucky Markey Cancer Center’s Research Communications Office assisted with manuscript preparation, the Biostatistics and Bioinformatics Shared Resource Facility provided statistical support, and the Biospecimen Procurement & Translational Pathology Shared Resource Facility provided IHC preparation and staining support; these Shared Resource Facilities are supported by NCI Cancer Center Support Grant (P30 CA177558). Acknowledgments: The University of Kentucky Markey Cancer Center’s Research Communica‐ tions Office assisted with manuscript preparation, the Biostatistics and Bioinformatics Shared Re‐ source Facility provided statistical support, and the Biospecimen Procurement & Translational Pa‐ thology Shared Resource Facility provided IHC preparation and staining support; these Shared Re‐ source Facilities are supported by NCI Cancer Center Support Grant (P30 CA177558).

Funders	Funder number
Biospecimen Procurement & Translational Pathology Shared Resource Facility
The Markey Biostatistics and Bioinformatics Shared Resource Facility
National Childhood Cancer Registry – National Cancer Institute	P30 CA177558
University of Kentucky Markey Comprehensive Cancer Center

Keywords

Glutaminase
Immunohistochemistry
In situ methods
Prognosis
Prostate

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers13092157

Cite this

@article{de5880e644d24f7ba9c70c0497e003ee,

title = "Evaluation of glutaminase expression in prostate adenocarcinoma and correlation with clinicopathologic parameters",

abstract = "High Glutaminase (GLS1) expression may have prognostic implications in colorectal and breast cancers; however, high quality data for expression in prostate cancer (PCa) are lacking. The purpose of this study is to investigate the status of GLS1 expression in PCa and correlated expression levels with clinicopathologic parameters. This study was conducted in two phases: an exploratory cohort analyzing RNA-Seq data for GLS1 from The Cancer Genome Atlas (TCGA) data portal (246 PCa samples) and a GLS1 immunohistochemical protein expression cohort utilizing a tissue microarray (TMA) (154 PCa samples; 41 benign samples) for correlation with clinicopathologic parameters. In the TCGA cohort, GLS1 mRNA expression did not show a statistically significant difference in disease-free survival (DFS) but did show a small significant difference in overall survival (OS). In the TMA cohort, there was no correlation between GLS1 expression and stage, Gleason score, DFS and OS. GLS1 expression did not significantly correlate with the clinical outcomes measured; however, GLS1 expression was higher in PCa cells compared to benign epithelium. Future studies are warranted to evaluate expression levels in greater numbers of high-grade and advanced PCa samples to investigate whether there is a rational basis for GLS1 targeted therapy in a subset of patients with prostate cancer.",

keywords = "Glutaminase, Immunohistochemistry, In situ methods, Prognosis, Prostate",

author = "Myint, \{Zin W.\} and Sun, \{Ramon C.\} and Hensley, \{Patrick J.\} and James, \{Andrew C.\} and Peng Wang and Strup, \{Stephen E.\} and McDonald, \{Robert J.\} and Donglin Yan and \{St. Clair\}, \{William H.\} and Allison, \{Derek B.\}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = may,

day = "1",

doi = "10.3390/cancers13092157",

language = "English",

volume = "13",

number = "9",

}

TY - JOUR

T1 - Evaluation of glutaminase expression in prostate adenocarcinoma and correlation with clinicopathologic parameters

AU - Myint, Zin W.

AU - Sun, Ramon C.

AU - Hensley, Patrick J.

AU - James, Andrew C.

AU - Wang, Peng

AU - Strup, Stephen E.

AU - McDonald, Robert J.

AU - Yan, Donglin

AU - St. Clair, William H.

AU - Allison, Derek B.

PY - 2021/5/1

Y1 - 2021/5/1

N2 - High Glutaminase (GLS1) expression may have prognostic implications in colorectal and breast cancers; however, high quality data for expression in prostate cancer (PCa) are lacking. The purpose of this study is to investigate the status of GLS1 expression in PCa and correlated expression levels with clinicopathologic parameters. This study was conducted in two phases: an exploratory cohort analyzing RNA-Seq data for GLS1 from The Cancer Genome Atlas (TCGA) data portal (246 PCa samples) and a GLS1 immunohistochemical protein expression cohort utilizing a tissue microarray (TMA) (154 PCa samples; 41 benign samples) for correlation with clinicopathologic parameters. In the TCGA cohort, GLS1 mRNA expression did not show a statistically significant difference in disease-free survival (DFS) but did show a small significant difference in overall survival (OS). In the TMA cohort, there was no correlation between GLS1 expression and stage, Gleason score, DFS and OS. GLS1 expression did not significantly correlate with the clinical outcomes measured; however, GLS1 expression was higher in PCa cells compared to benign epithelium. Future studies are warranted to evaluate expression levels in greater numbers of high-grade and advanced PCa samples to investigate whether there is a rational basis for GLS1 targeted therapy in a subset of patients with prostate cancer.

AB - High Glutaminase (GLS1) expression may have prognostic implications in colorectal and breast cancers; however, high quality data for expression in prostate cancer (PCa) are lacking. The purpose of this study is to investigate the status of GLS1 expression in PCa and correlated expression levels with clinicopathologic parameters. This study was conducted in two phases: an exploratory cohort analyzing RNA-Seq data for GLS1 from The Cancer Genome Atlas (TCGA) data portal (246 PCa samples) and a GLS1 immunohistochemical protein expression cohort utilizing a tissue microarray (TMA) (154 PCa samples; 41 benign samples) for correlation with clinicopathologic parameters. In the TCGA cohort, GLS1 mRNA expression did not show a statistically significant difference in disease-free survival (DFS) but did show a small significant difference in overall survival (OS). In the TMA cohort, there was no correlation between GLS1 expression and stage, Gleason score, DFS and OS. GLS1 expression did not significantly correlate with the clinical outcomes measured; however, GLS1 expression was higher in PCa cells compared to benign epithelium. Future studies are warranted to evaluate expression levels in greater numbers of high-grade and advanced PCa samples to investigate whether there is a rational basis for GLS1 targeted therapy in a subset of patients with prostate cancer.

KW - Glutaminase

KW - Immunohistochemistry

KW - In situ methods

KW - Prognosis

KW - Prostate

UR - https://www.scopus.com/pages/publications/85105061709

UR - https://www.scopus.com/inward/citedby.url?scp=85105061709&partnerID=8YFLogxK

U2 - 10.3390/cancers13092157

DO - 10.3390/cancers13092157

M3 - Article

AN - SCOPUS:85105061709

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 9

M1 - 2157

ER -

Evaluation of glutaminase expression in prostate adenocarcinoma and correlation with clinicopathologic parameters

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this